DE69034100D1 - Verktorvermittelte genominsertion und expression von dna in bcg - Google Patents

Verktorvermittelte genominsertion und expression von dna in bcg

Info

Publication number
DE69034100D1
DE69034100D1 DE69034100T DE69034100T DE69034100D1 DE 69034100 D1 DE69034100 D1 DE 69034100D1 DE 69034100 T DE69034100 T DE 69034100T DE 69034100 T DE69034100 T DE 69034100T DE 69034100 D1 DE69034100 D1 DE 69034100D1
Authority
DE
Germany
Prior art keywords
dna
genom
bcg
mediated
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69034100T
Other languages
English (en)
Other versions
DE69034100T2 (de
Inventor
Richard A Young
Anna Aldovini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Application granted granted Critical
Publication of DE69034100D1 publication Critical patent/DE69034100D1/de
Publication of DE69034100T2 publication Critical patent/DE69034100T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69034100T 1989-06-19 1990-06-18 Verktorvermittelte genominsertion und expression von dna in bcg Expired - Fee Related DE69034100T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36789489A 1989-06-19 1989-06-19
US367894 1989-06-19
PCT/US1990/003451 WO1990015873A1 (en) 1989-06-19 1990-06-18 Vector-mediated genomic insertion and expression of dna in bcg

Publications (2)

Publication Number Publication Date
DE69034100D1 true DE69034100D1 (de) 2003-10-23
DE69034100T2 DE69034100T2 (de) 2004-06-09

Family

ID=23449053

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69034100T Expired - Fee Related DE69034100T2 (de) 1989-06-19 1990-06-18 Verktorvermittelte genominsertion und expression von dna in bcg

Country Status (7)

Country Link
EP (1) EP0478664B1 (de)
JP (1) JPH04506297A (de)
AT (1) ATE250133T1 (de)
AU (1) AU5848090A (de)
CA (1) CA2063414A1 (de)
DE (1) DE69034100T2 (de)
WO (1) WO1990015873A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5807723A (en) 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
AU2221992A (en) * 1991-06-06 1993-01-08 Med Immune, Inc. Induction of immune response against tetanus toxin through administration of mycobacteria expressing tetanus toxin or fragments
AU2189392A (en) * 1991-06-13 1993-01-12 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
US6566121B1 (en) 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
EP0521220A1 (de) * 1991-06-14 1993-01-07 Institut Pasteur Immunogene rekombinante Actinomycetale
EP0625052A4 (de) * 1991-10-21 1995-07-19 Medimmune Inc Sekretionssignal von lipoproteinen kodierende dna enthaltener bakterieller expressionsvektor.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
EP0700445B1 (de) * 1993-06-04 2002-01-23 Whitehead Institute For Biomedical Research Stressproteine und ihre verwendung
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
CN1103781C (zh) 1993-11-23 2003-03-26 加利福尼亚大学 丰富的细胞外产物和其生产与使用方法
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
DE4425382C2 (de) * 1994-07-19 1997-08-14 Univ Hohenheim Salmonella-Lebendimpfstoff
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6221364B1 (en) * 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
DK1002110T3 (da) 1997-08-05 2003-05-26 Stressgen Biotechnologies Corp Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
AU5926700A (en) 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
WO2001051081A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
KR100919266B1 (ko) 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
BR0206995A (pt) 2001-02-05 2005-08-16 Stressgen Biotechnologies Corp Tratamento do vìrus da hepatite b
WO2004016280A1 (ja) * 2002-08-16 2004-02-26 Japan Science And Technology Agency 組換えｂｃｇワクチン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE132195T1 (de) * 1987-03-02 1996-01-15 Whitehead Biomedical Inst Rekombinant-mykobakterielle impfstoffe
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine

Also Published As

Publication number Publication date
EP0478664B1 (de) 2003-09-17
EP0478664A1 (de) 1992-04-08
JPH04506297A (ja) 1992-11-05
ATE250133T1 (de) 2003-10-15
CA2063414A1 (en) 1990-12-20
DE69034100T2 (de) 2004-06-09
AU5848090A (en) 1991-01-08
WO1990015873A1 (en) 1990-12-27

Similar Documents

Publication Publication Date Title
DE69034100D1 (de) Verktorvermittelte genominsertion und expression von dna in bcg
ATE256730T1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
ATE133681T1 (de) Mykobakterielle rekombinanten und peptide
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
DE69636890D1 (de) Neuartige ctla4/cd28 liganden und deren anwendungen
PT85977A (en) Process for the preparation of human apolipoprotein ai and their variant forms by recombinant dna methods
NO885664D0 (no) Polypeptider og derivater derav, samt anvendelse i farmasoeytiske og diagnostiske preparater.
ATE215124T1 (de) Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
EP1208196A4 (de) 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
CA2251262A1 (en) Nucleic acid encoding a nervous tissue sodium channel
DE68914397D1 (de) Menschliches Lymphotoxin.
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
DE3876227D1 (de) Malaria-spezifische dna-sequenzen, ihre expressionsprodukte und deren verwendung.
DK43991A (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
DE60234047D1 (de) 15603, ein mitglied der humanen ionenkanal-familie
DK1241186T4 (da) Humant vækststandsende specifikt gen-6 (gas-6) og nukleinsyrer kodende derfor
ATE492640T1 (de) Loslösendes protein 5 - ucp5
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
DK56995A (da) Rekombinante lymphotoxin-varianter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee